Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma

Stopped Phase 2 part of the trial will no longer continue since the protocol competes with another TPI287 protocol in outside institution supported by the sponsor.

Conditions

• Brain Neoplasms
• Central Nervous System Neoplasms

Interventions

• DRUG: TPI287
• DRUG: Bevacizumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

• [object Object]